Cellectar Biosciences
CLRB
45 hedge funds and large institutions have $36.3M invested in Cellectar Biosciences in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 15 increasing their positions, 4 reducing their positions, and 3 closing their positions.
633% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 3
275% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 4
73% more funds holding
Funds holding: 26 → 45 (+19)
52% more capital invested
Capital invested by funds: $23.9M → $36.3M (+$12.5M)
0.14% more ownership
Funds ownership: 2.33% → 2.48% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
81% less call options, than puts
Call options by funds: $93K | Put options by funds: $499K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.21M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.56M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.89M |
| 4 |
Barclays
London,
United Kingdom
|
+$1.22M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$893K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$5M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.66M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$1.92M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.21M |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
-$25.4K |
CLRB Hedge Fund Activity: Q1 2024 in Review
45 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2024, worth a combined $36.3M — up 52% from $23.9M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CLRB positions and 3 closed out — a net gain of 19 holders — while 15 added to existing stakes and 4 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $3.21M. The largest seller was Rosalind Advisors, cutting an estimated $5M.
- 45 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2024, up from 26 in Q4 2023.
- Funds reported $36.3M of Cellectar Biosciences stock for Q1 2024, up 52% quarter-over-quarter.
- 22 funds opened new Cellectar Biosciences positions in Q1 2024 and 3 closed out, a net change of +19 holders.
- The largest Cellectar Biosciences buyer in Q1 2024 was AIGH Capital Management, an estimated $3.21M added.
- The largest Cellectar Biosciences seller in Q1 2024 was Rosalind Advisors, an estimated $5M sold.
Based on aggregated 13F filings for Q1 2024.